Developing the world's most advanced organ-on-chip technology to enable pre-clinical trials on-chip that can predict drug failure in human trials.
It takes on average $2.6B and 12 years to discover one successful drug because 90% drug candidates fail at the late and expensive clinical trial stages. The reason is that there are no accurate methods of drug performance prediction. Current methods used in the pre-clinical stage rely on tissue models that do not behave like in-vivo human tissues. Therefore, the reaction of these grown tissues to drugs is different from their reaction in the human body.
DLOC has developed and patented the most advanced organ-on-chip device on the market that allows for growing 3D human tissue in-vitro while preserving in-vivo tissue properties. DLOC has also developed and patented another automated device that operates multiple connected chips of different tissue types, to create a human-on-chip model. With DLOC’s technology, it is possible to test drugs on human models and accurately predict a drug’s success and failure prior to clinical trials. DLOC aims to offer pre-clinical trials on-chip testing service that would significantly reduce the cost of drug development and increase trial safety.
DLOC was able to successfully grow and maintain over a prolonged period of time healthy and diseased tissue models. The images below display the grown tissue. We are currently setting up collaborations with multiple pharma companies to test the toxicity & efficacy of preclinical drugs and predict drug dosage on a variety of organ models.
Awards & Achievements
Stars-of-science 1st-prize -Qatar foundation
Arab Entrepreneurship Rally 1st prize- Bahrain Chamber of Commerce
Grant award - Kuwait Chamber of Commerce
LIRA Forum 1st-prize - Lebanese Ministry of Industry
MIT Enterprise Forum 3rd prize - MITEF Pan Arab
Darwazah Student Entrepreneurship contest 1st prize - AUB Darwazah Center
Supporters & Collaborators
DLOC Biosystems spun off from the mechanical engineering department at the American University of Beirut (AUB). The journey started with a research project that aimed to study breast cancer metastasis in mammary ducts. The research gave birth to new methods and tools in tissue culture that provided the seeds from which DLOC's technology evolved. In its early days, the startup was incubated at the AUB Darwazah Center. DLOC then went on to secured funding through winning multiple local and international entrepreneurship competitions, including the Stars of Science innovation contest. With this funding DLOC significantly improved, tested, validated, and patented its technology. At the current time, DLOC has a team of 10 people working on innovating new technologies, acquiring new customers, and securing new funding to pursue our mission.
Our Mission & Vision
Vision: to create the best invitro biomimetic platform that enables safer, more precise, and more personalized medicine.
Mission: to create the easiest-to-use and most mimetic organ on a chip device for in-vitro testing. The arrangement of cells within a tissue is organized to enable its specific function. We will achieve this by developing innovative technology, that allows for growing tissue with the exact tissue structure and spatial assembly of the different tissue types and extracellular matrix components. This allows for creating an accurate replica of the invivo cell and tissue interaction within its micro-environment.
"Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less"